C
221.38
0.00 (0.00%)
| Penutupan Terdahulu | 221.38 |
| Buka | 221.38 |
| Purata Dagangan (3B) | 1,360,071 |
| Modal Pasaran | 6,961,583,616 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.75 |
| Harga / Jualan (P/S) | 0.990 |
| Harga / Buku (P/B) | 16.48 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -35,743.71% |
| EPS Cair (TTM) | -26.68 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.89% |
| Nisbah Semasa (MRQ) | 3.87 |
| Aliran Tunai Operasi (OCF TTM) | -191.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.87 M |
| Pulangan Atas Aset (ROA TTM) | -55.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -299.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cidara Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | -3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.12% |
| % Dimiliki oleh Institusi | 73.93% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 145.00 (RBC Capital, -34.50%) | Beli |
| Median | 140.00 (-36.76%) | |
| Rendah | 135.00 (Needham, -39.02%) | Beli |
| Purata | 140.00 (-36.76%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 104.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 07 Nov 2025 | 135.00 (-39.02%) | Beli | 104.39 |
| RBC Capital | 07 Nov 2025 | 145.00 (-34.50%) | Beli | 104.39 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |